mass spec perform
updat forecast estim jun
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim jun
price data jun
rate updat jun
currenc amount express
valuat growth profit
methodolog valu compani
water long-term prospect remain solid compani
continu churn product sought client base
build sizeabl exist instal base firm enviabl
technolog prowess lead share mani market
serv like continu yield return capit well
peer
water make instrument applic bread butter
chromatographi enjoy sizeabl market share
continu solidifi posit steadi flow new
product compani also command strong market share
mass spectrometri one life scienc firm
high-end product suit address need
research water strategi build strong posit
high-end research market leverag platform
technolog know-how expand adjac market
appli market qualiti assurance/qu control
product abl play across spectrum product
sophist allow command higher share
consum wallet particularli pharmaceut compani
reduc cyclic associ high-end instrument
exposur academ govern market
water still expos capit spend cycl larg portion
pharmaceut end market stay strong grow
complex research drive adopt increasingli
particularli bit unpredict could
water strength manag team consid
among best life scienc space knack wise capit
deploy impress compani steer away larg
supplement bolt-on deal space technolog
advantag often fleet stronghold high-end
liquid chromatographi direct result manag focu
instead
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
water provid analyt instrument pharmaceut biochem
industri custom roughli half sale attribut
instrument includ liquid chromatographi mass spectrometri
platform well thermal analysi tool consum servic
account remaind sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
weak mass spec perform apr
water deliv rare perform hiccup first
quarter revenu fall short expect mainli
weak mass spectrometri compani
underplay signific miss attribut
one-off issu rather structur problem increas
competit mass spec weak come
previous strong end market strong
reason question manag confid underscor
reiter full-year guidanc fair valu estim
wide moat rate intact
mass spec revenu weak surpris especi
heel high-single-digit growth manag
attribut revenu declin categori number
nonmateri factor first quarter
smallest one term capit sale biomed research
demand lumpi vagu commentari
sale realign unit state quarter
last one particularli curiou us -- detail
provid realign
implement buy lumpi small quarter
rational howev comfort compani
maintain full-year guidanc despit rather sizabl
quarterli miss manag
reput overpromis underdeliv
unless hear someth differ come day
regard mass spec dynam compani main
competitor space plan keep number
asid mass spec india segment fare well
thermal analysi segment perform china
europ deliv good growth pharmaceut demand
remain strong recur revenu
quarter compani perform earn line
line expect slightli increas
guidanc mainli due currenc buyback
valuat growth profit jan
rais fair valu estim per share
due cash flow realiz sinc last report updat
given compani strong technolog new-product
introduct like perform better
peer wari potenti deceler
pharmaceut biotech spend end market
strong sever year compani tilt
toward instrument could leav somewhat expos
deceler demand expect next year
nonetheless anticip high-single-digit growth
end market academ govern custom
jointli account low-teen percentag total sale
make compani sensit potenti weaker
spend europ compani leverag
technolog expand presenc appli end market
strategi target low-end user reson
well emerging-market custom contract
research organis emerg market grow
import compani made
sizeabl invest infrastructur area
support growth project mid- high-single-digit growth
long term think long-term oper margin
exclud amortis restructur stay close
next five year new product
introduct well outsourc manufactur
oversea off-set increas price competit
divis instrument mid- high-single-digit
growth chemistri consum forecast
ta divis grow low singl digit yield
growth rate correspond fair valu estim
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
assign water wide moat rate result
lead posit liquid chromatographi mass
unmatch -- water appear consist step
ahead competit technic paramet
instrument end-market applic
technolog advantag typic fleet lag time
allow compani erect much stronger competit
barrier switch cost water platform fairli
long-liv -- upgrad cycl could five year
-- requir sizeabl up-front invest form
train time resourc instrument also becom
drug-manufactur process
research use one platform earli stage drug
research often use platform
entir drug research process could last
year chang manufactur includ
test impur measur molecular weight
shape would requir approv regul larg
instal base give compani steadi stream
consum revenu sale column
smooth lumpi associ capit purchas
equip wide moat support
robust oper margin excess sinc
return capit past decad
abl maintain gap
technolog peer see flaw
armour term perform effici
importantli technolog superior past
decad provid compani much stronger
grow term import moat compon -- rapidli
increas instal base correspond switch
cost water posit high-end instrument
defens result platform slide
adopt curv favour moat trend
lower-end user primari target earli day
upsid scenario incorpor strong uptak
firm new ms offer steadi price lc product
line increas penetr appli market
scenario cheaper sourc stem grow
utilis low-cost manufactur also provid buffer
potenti price pressur allow water
maintain expand robust gross margin
share could worth per share assum
compani technolog far success
pri market share away rival plausibl
competit could eventu catch lose
technolog superior would forc water
cognis price strategi could potenti
result gross margin move direct peer
trim basi point per year gross
margin without correspond cut firm research
develop expenditur would bring fair valu
estim per share fair valu estim would
impli forward earn multipl midteen
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
compani technolog provid previous
untap custom base offer opportun growth
offset factor firm somewhat limit product
offer could provid open
one-stop-shop firm like thermo fisher client
seek reduc total number vendor use
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
odomin acquiti uplc platform
high-end research given pathway appli
market compani product suit expand
presenc adjac area
oth firm thermal instrument divis gener
oper margin excess
busi requir minim capit invest
return capit well overal
oemerg market benefit increas
market presenc gener drugmak
increas food safeti environment test
chines govern
owat -base manufactur expos
compani foreign exchang risk
owat revenu base could expos
pullback academ spend rival
sale come expens lab
oth compani face formid competit ms
like thermo fisher market share
slip somewhat past year
competitor activ new product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
water carri million long-term debt balanc
sheet gradual increas
balanc billion current firm appear
comfort debt load cash-plus-invest
balanc exce indebted cash flow
healthi think firm could take addit debt
need oper strategi requir limit capit
invest compani overli acquisit
tend expand area outsid immedi
expertis instead choos return capit sharehold
form robust share repurchas sinc water
reduc outstand share count
shown sign slow
histor reli larg pharmaceut
compani sizeabl portion revenu although
client account total sale
capital-spend environ could tighten
firm could neg affect sale growth
addit sale contract research organis
industri client highli cyclic could caus
swing order particularli expens ms
instrument demand academ govern
market could come pressur unit state
current administr continu explor avenu
lower spend continu strong demand china
conting growth research pharmaceut
end market industri spend still repres
lion share chines spend life scienc tool
unlik return previou rapid growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
new york mellon corp
share
fund
share
fund
maintain exemplari stewardship rate
comfort new leadership team chri connel
compani new ceo former presid
restor therapi group appear
content stay cours unlik make
decis would dramat overhaul firm
strategi appoint product long search
dougla berthiaum replac gener
chang oper structur
approach focus
berthiaum leadership grew
industri leader return invest capit becam
envi industri new leadership team
far follow berthiaum footstep compani
disciplin
invest lieu acquisit yield
superb product portfolio continu separ firm
peer water life scienc firm
coverag wide econom moat testament
leadership prioriti place intern research
develop capit deploy firm stock
perform superior competitor
investor tend appreci commit
long-term strategi compani also disciplin
invest area outsid research
macroeconom environ deliv earn growth
even time declin top line
favour compani align execut compens
packag busi perform view water
one compani approv pay
structur heavili weight toward long-term
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
water corpor finish year strong
water corpor report strong last-quart full-
year result mainli line expect
maintain fair valu estim
last-quart sale growth constant currenc
driven pharma custom governmental/
academ sector global industri sale flat
tough comparison prior-year quarter market
rebound sluggish third-quart perform
fuel increas spend mid-size larg
pharmaceut custom demand pharma product
also strong china india
fiscal year end market post posit sale
growth sale largest market pharmaceut grew
constant currenc industri government/
academ sale constant rate grew
respect geograph full-year sale grew
asia europ driven pharmaceut custom
biomed research sale america
flat previou year sinc declin first half
year off-set quarter growth believ
chines market sustain double-digit mid-term growth
sinc manag commit take advantag
chines govern key initi healthi china
food safeti environment concern
expect drive industri pharma demand
exclud million incom tax charg trigger
tax cut job act adjust ep fiscal year
increas compar
fiscal-year project ep growth
medium term given slight increas gross margin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
